MedTrace Logo

A First-in-Human Study of QY211 Gel in Adult Subjects

NCT05843422 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2023-05-06

No results posted yet for this study

Summary

This is a phase Ia/Ib,Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of Single and Multiple Topical Doses of QY211 Gel in Healthy Chinese Subjects and Patients with Mild to Moderate Atopic Dermatitis

Conditions

Interventions

DRUG

0.3% QY211 Gel or placebo

QY211 Gel or placebo topical applied to skin

DRUG

0.8% QY211 Gel or placebo

QY211 Gel or placebo topical applied to skin

DRUG

1.5% QY211 Gel or placebo

QY211 Gel or placebo topical applied to skin

DRUG

0.1% QY211 Gel or placebo

QY211 Gel or placebo topical applied to skin

Sponsors & Collaborators

  • E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2024-10-23
Completion
2024-10-23

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05843422 on ClinicalTrials.gov